Tetra Discovery Partners today announced that the U.S. Patent and Trademark Office has issued a third patent covering the company’s selective phosphodiesterase-4D (PDE4D) inhibitor, BPN 14770, and related compounds. The new patent, US 10,093,686, covers claims for the use such compounds in the treatment of mild cognitive impairment, Parkinson’s disease, stroke and ischemia.
“This new patent further builds on the intellectual property protections for our lead compound, adding to the previously issued patents covering BPN 14770’s composition and use in the treatment of Alzheimer’s disease,” said Mark Gurney, Ph.D., Chairman and Chief Executive Officer of Tetra. "We believe this compound has the potential to benefit the lives of many patients with cognitive disorders, Alzheimer’s disease, and related illnesses.”
“We are pleased to add this patent to the growing Worldwide IP portfolio covering this exciting new compound,” said Chad Coberly, JD, Senior Vice President, Clinical, Regulatory & Legal Affairs at Tetra. “Related patents have now issued in Japan, China, and Israel and prosecution continues in Europe and in several other potentially significant markets for the new therapy.”